<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table III Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0–8.5*</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<thead>
<tr>
<th>Event</th>
<th>Gemfibrozil</th>
<th>Placebo at</th>
<th>Gemfibrozil:Placebo</th>
<th></th>
</tr>
<tr>
<th></th>
<th>at Study</th>
<th>Study Start</th>
<th>Hazard</th>
<th>Cl Hazard</th>
</tr>
<tr>
<th></th>
<th>Start</th>
<th></th>
<th>Ratio†</th>
<th>Ratio‡</th>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="5">
<paragraph>*Intention-to-Treat Analysis of originally randomized patients neglecting the open-label treatment switches and exposure to study conditions.                                                                                                                                                                                              †Hazard ratio for risk event in the group originally randomized to Gemfibrozil Tablets compared to the group originally randomized to placebo neglecting open-label treatment switch and exposure to study conditions.                                                                                ‡95% confidence intervals of Gemfibrozil Tablets:placebo group hazard ratio                                                                                        §Fatal and non-fatal myocardial infarctions plus sudden cardiac deaths over the 8.5 year period. </paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td> Cardiac Events§</td>
<td> 110</td>
<td> 131</td>
<td> 0.80</td>
<td> 0.62–1.03</td>
</tr>
<tr>
<td>Cardiac Deaths</td>
<td> 36</td>
<td> 38</td>
<td> 0.98</td>
<td> 0.63–1.54</td>
</tr>
<tr>
<td>Non-Cardiac Deaths</td>
<td> 65</td>
<td> 45</td>
<td> 1.40</td>
<td> 0.95–2.05</td>
</tr>
<tr>
<td> All-Cause Mortality</td>
<td> 101</td>
<td> 83</td>
<td> 1.20</td>
<td> 0.90–1.61</td>
</tr>
</tbody>
</table>